Telford, PA—Secant Group, a leading innovator in the design, development, and manufacture of implantable medical textile components for medical devices, has been named 2022 Supplier of the Year by Edwards Lifesciences, the global leader in patient-focused medical innovations for structural heart disease and critical care and surgical monitoring.
“We’re thrilled to receive this prestigious award from Edwards Lifesciences. This is a testament to Secant’s rigorous quality standards and multidisciplinary teamwork that enables Edwards Lifesciences to advance their innovative, life-saving devices with our implantable textile solutions. We’re proud to be a long-serving partner of Edwards and look forward to collaborating with them on new solutions for years to come,” said Karen West, CEO, Solesis, parent company of Secant Group.
In 2022, Secant Group was also the first-ever supplier awarded Gold Status by Edwards Lifesciences.
“Achieving the highest possible supplier status demonstrates Secant Group’s deep commitment to serving customers with nimble, quality-driven capabilities and continuous improvement initiatives, all designed to consistently fulfill customer needs,” said Jeff Robertson, Chief Operating Officer of Solesis, and President, Secant Group.
Operating through its subsidiaries Charter Medical, Polyzen, and Secant Group, Solesis develops and manufactures critical biomaterials components and technologies for customers in the medical device, biopharmaceutical, and cell and gene therapy industries. Solesis also innovates on behalf of its customers, including through Secant Group’s patented polymer platform poly(glycerol sebacate) (PGS), which demonstrates unparalleled benefits over traditional polymers currently used for drug delivery and medical device applications. Headquartered in Telford, PA, Solesis employs 450 people across five production facilities located in Pennsylvania and North Carolina. For additional information, please visit our website: www.solesis.com.